Preclinical evaluation of anti-hepatitis B virus antibody---A review
LI Meng, SUN Gui-Qin, WANG Lei, CHEN Li
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Abstract：Hepatitis B virus (HBV) infection is a global medical concern with huge social and economic impacts. In the current practice, hepatitis B immunoglobulin (HBIG) prepared from pooled serum of immunized donors is prescribed to prevent HBV transmissions, such as mother-to-child transmission, acute exposure, and donor-receptor infection for orthotopic liver transplant patients. As a plasma-derived product, the clinical application of HBIG is limited by serum supply, potential of unknown pathogens and other risk factors in the pooled blood, and up-limits of functional dose. Although recombinant anti-HBV monoclonal antibody is being sorted as a practical alternative for HBIG, its research and development is in a relatively slow pace comparing to the other products. One of the most critical speed-limiting steps is the lack of an established preclinical evaluating system for anti-HBV monoclonal antibodies. Current research progress on functional evaluation of anti-HBV antibodies are reviewed in this paper.
李蒙，孙桂芹，王蕾，陈力. 抗乙型肝炎单克隆抗体药物的临床前药效学评价[J]. 微生物与感染
, 2013, 8(4): 248-254.
LI Meng, SUN Gui-Qin, WANG Lei, CHEN Li. Preclinical evaluation of anti-hepatitis B virus antibody---A review. Journal of Microbes and Infections, 2013, 8(4): 248-254.
